Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule,,Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for,Clinical Development in Chronic Hepatitis C Virus Infection
...SAN DIEGO June 20 2007 /PRNewswire-FirstCall/ -- AnadysPharmaceutic... We have identified a small-molecule non-nucleoside inhibitorof the ...Preclinical Study Results ...In a series of in vitro pre-clinical studies ANA598 demonstratedexcel...
SAN DIEGO, June 20, 2007 /PRNewswire-FirstCall/ -- Anadys
Pharmaceuticals, Inc. , a biopharmaceutical company committed to
the discovery, development and commercialization of novel medicines
for the treatment of hepatitis and cancer, announced today that it
has nominated ANA598 as a candidate for clinical development as an
orally-administered direct antiviral for the treatment of chronic
hepatitis C virus (HCV) infection.
"We have identified a small-molecule, non-nucleoside inhibitor
of the NS5b polymerase that, based on pre-clinical studies
conducted to date, has shown favorable antiviral, metabolic,
pharmacokinetic, and preliminary toxicologic properties, and is the
culmination of several years of work in our HCV direct antiviral
discovery program," said Lawrence C. Fritz, Ph.D., president and
chief executive officer of Anadys. "We are now conducting
additional pre-clinical studies in anticipation of submitting an
Investigational New Drug application (IND) in the second quarter of
2008."
Preclinical Study Results
In a series of in vitro pre-clinical studies ANA598 demonstrated
excellent potency against HCV genotype 1 NS5b polymerase and potent
activity in HCV replicon assays. The compound also displayed very
good in vitro metabolic stability and did not significantly inhibit
human CYP enzymes, suggesting a low potential for drug-drug
interactions. Extending these in vitro findings, in vivo
preclinical studies of ANA598 demonstrated high oral
bioavailability and good tolerability. Also, drug levels were
sustained in the plasma and in the liver, the principal site of HCV
replication.
"The current standard of care is inadequate for many chronic HCV
patients, including about half of those with genotype 1 disease,"
said Steve Worland, Ph.D., president, Pharmaceuticals. "We believe
ANA598 possesses favorable characteristics that may enable it to
play an important role in future HCV thera
'"/>
Page: 1 2 3 4 Related medicine technology :1.
Anadys Reports Preclinical Data Showing ANA773 Promotes Anti-Tumor
Activity of Natural Killer Cells2.
BioSante Pharmaceuticals Announces New Findings for Potential Bird
Flu Vaccine3.
Portola Pharmaceuticals Announces Positive Data from a Phase II
Study of its Factor Xa Inhibitor at the XXI Congress of the
International Society on Thrombosis and Haemostasis4.
Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for
Oral Oleoyl-estrone5.
Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging
Growth Opportunities Conference6.
Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin
Emerging Growth Conference7.
EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin
Emerging Growth Opportunities Conference8.
Pro-Pharmaceuticals Updates Progress of Clinical Trials &
Davanat 505 (b)(2) Filings9.
Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III
Data with Rifamycin MMX in Infectious Diarrhea10.
Portola Pharmaceuticals Announces Positive Phase II EXPERT Results
and Additional Oral and Poster Presentations at the XXI Congress of
the International Society on Thrombosis and Haemostasis (ISTH)11.
Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
(Date:11/25/2009)...e/--AMPACFineChemicalsLLC(AFC),asubsidiaryofAmeric...hatitreceivedtheEnvironmentalResponsibilityandSust...mmit,sponsoredbytheCaliforniaManufacturersandTechn...ssociation(IEA)andtheChemicalIndustryCouncilofCali...sawardavailablefromallthreeorganizationsandgainssu...
(Date:11/25/2009)...rstCall/--Abaxis,Inc.(Nasdaq: ABAX ),amedicalprodu...ystems,announcedtodaythatClintSeverson,chairmanand...perJaffrayHealthCareConferenceonWednesday,December...YorkPalaceHotelinNewYorkCity. ,, AboutAbaxis ...ebloodanalysissystemsforuseinanyveterinaryorhumanp...
(Date:11/25/2009)...ker.comannouncesthatanewmarketresearchreportisavai...Trends ,, http://www.reportlinker.com/p01642...espreadavailabilityofgenericdrugs,emergenceofpainm...atedthepaceofgrowthinthepainmanagementmarket.Healt...pedemandforservices,drugsanddevices.Themarketispri...
Breaking Medicine Technology:AMPAC Fine Chemicals Receives Prestigious Award at California's Annual Statewide Environmental Summit 2Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Avantpage Celebrates Its 26quot 3BLucky 13th 26quot 3B Anniversary with Report on Recent History Emerging Trends in Translation 60673 1Avantpage Celebrates Its 26quot 3BLucky 13th 26quot 3B Anniversary with Report on Recent History Emerging Trends in Translation 60673 2Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 1Glencoe Software to Support the ASCB Stimulus Grant to Build Virtual Image Library of the Cell 10625 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 1RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 2RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 3RNL BIO Rescues a College Student from Autoimmune Hearing Loss 14716 4...rica, Inc. (Other,OTC: RXAF.PK), announced today t...e under the symbol RXAF.PK and that the name "Diam...o longer be used as part of,the company,s operatio...in a reverse merger,completed in May 2007 with Dia...wholly owned subsidiary, Rx Africa (Ethiopia) PLC ...
...rma Incorporated,(Nasdaq: VPHM ) today announced ...e officer of ViroPharma, will present at the Acume...nference at 8:50 A.M. ET on Tuesday,November 6, 20...alace,Hotel. ViroPharma,s presentation will be we...harma.com and available through November 20, 2007...
Other Medicine Technology:Rx for Africa, Inc. Now Trading Under New Symbol (RXAF.PK) 2(Date:11/26/2009)...g or too heavy can lead to strains or worse , ...e may be nothing wrong with stuffing your turkey f...same thing with your suitcase as you pack for holi...ed in 2008 in U.S. hospital emergency rooms, docto...for luggage-related injuries, such as muscle strai...
(Date:11/26/2009)... No more letters from the North Pole, Textsant...essages from Santa , Nort...rational efficiencies at the North Pole Santa Clau...en all over the globe informed of his Christmas pr...;s research department have identified a large and...
(Date:11/26/2009)... Research Triangle Dental (RTDental), a leadin... today announced the expansion of its services to ... Dr. Doug Macmillan. , ... pleased to announce that Dr. Doug Macmillan, an e... an additional advanced training seminar. RTDenta...
(Date:11/26/2009)... Ennis & Ennis, P.A. is offering free nati... and Yasmin birth control pills who have suffered ...Stroke, Heart Attack or other related cardiac issu...l toll free at 1-800-856-6405 or go to the firm&rs...l out an online case evaluation form. , ...
(Date:11/25/2009)....,Nov.25/PRNewswire/--TheBartleHallConventionCente...niconDec.9-10,whenKansasCityhoststhelatestinaserie...isfreecliniceventhasthepotentialtobethebiggestoney...ndbeheldonweekdaysinsteadofoveraweekend,"SheriWood...ndpresidentoftheNationalAssociationofFreeClinics(N...
Breaking Medicine News(10 mins):Health News:Pack Right for the Holidays to Avoid the ER 2Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 2Health News:Ennis & Ennis, P.A. Announces Nationwide Free, Confidential, Consultations For Users Of Yaz And Yasmin Birth Control Pills 3Health News:Kansas City Prepares for Largest Free Health Clinic 2...nd out that sex differences in sleep patterns do e...n.
The researchers had carried out a national s...s and older in the city of Taiwan. The researchers...at there is a consistent difference between men an...
...the journal Neuropsychology// researchers have exp...tand sarcasm.
The study made by scientists fr...derstand sarcasm by giving their study participant... with posterior-lobe damage and 17 healthy control...
...at delaying pregnancy may result in shortened life... more women deciding to put off pregnancy for the ...nancy for women across the globe. Delaying in gett...pregnancy is being linked to lessening of life exp...
...f narcotics for chronic pain in elderly works, as ...ose. On the other hand, the use of the drug for yo...dosage with serious health repercussions.
T...fibromyalgia, arthritis and many such conditions. ...
...possible to use the human cells immune process to ...is for the first time scientists feel that it may ... virus in a novel HIV therapy. The process is call...ing, can ultimately destroy the RNA of the virus. ...
...cientist of Vanderbilt University have developed a... into neural circuits that play a role in developm... that make us apply previously learned rules on ne... the scientists in understanding the role played b...
Other Medicine News:... a synonym for pipetting accuracy, a smooth stroke...ing comfort. Its single, multifunctional button is... as well as eject the tip. Product features: Epp...y and precision. Ejection sleeve can be removed t...
Pipetman P20
Hydro-Therm™ Small Volume HME with Flextube Patient Connection
...right product for any patient ranging from pediatr...nts with tracheotomies. These products offer super...l care applications., ,The Unti-Mist HME and HME/...d staff members. This entire product line of unti-...
Medicine Products: